DDInter1366 DDInter1376
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Oxycodone {u} (Compound) resembles {v} (Compound) Hydromorphone
Oxycodone {u} (Compound) resembles {v} (Compound) Methylnaltrexone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxone
Oxycodone {u} (Compound) binds {v} (Gene) CYP3A4
Oxycodone {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Oxycodone {u} (Compound) causes {v} (Side Effect) Regurgitation
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Chloramphenicol
Oxycodone (Compound) resembles Hydromorphone (Compound)
Oxycodone (Compound) resembles Methylnaltrexone (Compound)
Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Oxycodone (Compound) binds CYP3A4 (Gene)
Oxycodone (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Oxycodone (Compound) causes Regurgitation (Side Effect)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Oxycodone may lead to a major life threatening interaction when taken with Chloramphenicol